Email Us
Call Us
Altogen Labs is now offering expedited PCR analysis services for most variants of COVID-19, including the highly transmissible Omicron variant. Results are guaranteed the next day. The price for this service is $250. Altogen Labs offers PCR tests only. How does it work? Submitting your sample for PCR testing at Altogen Labs is done at… Continue Reading
News
Altogen Labs Brain Cancer Model Collection Covers Twelve Validated Glioblastoma and Neuroblastoma Xenografts
AUSTIN, Texas – May 18, 2021 – Altogen Labs today detailed its brain cancer model collection, comprising twelve in-house validated xenografts spanning glioblastoma, glioma, and neuroblastoma (altogenlabs.com/xenograft-models). Glioblastoma remains the most lethal primary brain tumor, and the reasons it defeats therapy — diffuse invasion into surrounding parenchyma, resistance to conventional treatment, and a physical barrier… Continue Reading
Altogen Labs Biocompatibility Testing Services Support Medical Device and Combination Product Development
AUSTIN, Texas – April 3, 2021 – Altogen Labs today detailed its biocompatibility testing services, extending the company’s preclinical safety capability to medical device developers and sponsors of drug-device combination products. Device and combination product development follows a different regulatory path than small molecules, but it rests on the same foundation: demonstrating that materials in… Continue Reading
Altogen Labs Blood-Brain Barrier Model Supports CNS Drug Development Programs
AUSTIN, Texas – January 28, 2021 – Altogen Labs today highlighted its blood-brain barrier model, giving sponsors developing central nervous system therapeutics a defined system for assessing whether a compound can reach its target. CNS drug development carries the highest attrition rate in the industry, and the reason is rarely potency. Compounds that inhibit their… Continue Reading
Altogen Labs RNAi Manufacturing and CRO Services Support Oligonucleotide Programs at Scale
AUSTIN, Texas – December 20, 2020 – Altogen Labs today detailed its RNAi manufacturing and contract research services, supporting oligonucleotide programs from early design work through material supply for in vivo studies. Oligonucleotide programs have a distinctive supply problem. In vivo studies consume material at scale – a single tissue-targeted delivery study can require substantial… Continue Reading
Altogen Labs Tests Botanical Extracts, Natural Products, and Cosmetic Formulations
AUSTIN, Texas – November 30, 2020 – Altogen Labs today highlighted its testing services for botanical extracts, natural products, and cosmetic formulations, applying pharmaceutical-grade methodology to product categories that frequently receive far less rigorous evaluation. Natural products are frequently investigated for potential anticancer, anti-inflammatory, dermatological, antimicrobial, and other biological activities. However, the strength of these… Continue Reading
Altogen Labs Melanoma Model Collection Combines Human Xenografts with B16 Syngeneic Platform
AUSTIN, Texas – October 24, 2020 – Altogen Labs today detailed its melanoma model collection, pairing seven validated human melanoma xenografts with the B16 syngeneic murine model in both subcutaneous and metastatic formats. Melanoma occupies a distinctive position in oncology drug development. It was the tumor type where checkpoint blockade first demonstrated durable benefit, and… Continue Reading
Altogen Labs Liver Cancer Model Collection Spans Human Xenografts and Syngeneic Murine Models
AUSTIN, Texas – August 15, 2020 – Altogen Labs today detailed its liver cancer model collection, combining six validated human hepatocellular carcinoma xenografts with two syngeneic murine allograft models. Hepatocellular carcinoma presents a particular modeling challenge. It arises against a background of chronic inflammation and fibrosis, and its response to immunotherapy — now central to… Continue Reading
Altogen Labs Expands GLP Preclinical Efficacy and In Vivo Toxicology Capacity for Uninterrupted Drug Development
AUSTIN, Texas – June 8, 2020 – Altogen Labs, a highly reputable GLP-compliant contract research organization (CRO) headquartered in Austin, Texas, today reaffirmed the full availability of its preclinical efficacy and in vivo toxicology services to pharmaceutical, biotechnology, and academic clients worldwide. As announced through Business Wire in May 2020, Altogen Labs has remained fully… Continue Reading
Characterizing Novel Inhibitor Activity
Publication [Download PDF]: Alexandra Tyulyandina, Daniel Harrison, Wei Yin, et al. Invest New Drugs 35: 127–133. doi: 10.1007/s10637-016-0400-5 Based on data from 2013-2015, about 38% of the population will be diagnosed with some type of cancer during their lifetime, and there is an ongoing need for improved treatment techniques. Some chemotherapy agents are specific to… Continue Reading